NEUROCENTRIA
Neurocentria is a clinical-stage pharmaceutical company founded with the mission to discover and develop treatments for neurological diseases, including cognitive impairment and neuropsychiatric disorders. Neurocentria's research has focused on synaptic function, the elemental unit of neuronal communication and whose dysfunction is a common factor underlying both cognitive impairment and neuropsychiatric disorder. Two decades of research at Stanford, MIT, and Tsinghua University culminated in an understanding of the biology needed to restore synaptic function.
NEUROCENTRIA
Social Links:
Industry:
Health Care Pharmaceutical
Founded:
2005-01-01
Address:
Walnut Creek, California, United States
Country:
United States
Website Url:
http://www.neurocentria.com
Total Employee:
1+
Status:
Active
Contact:
925-954-4868
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon Content Delivery Network Euro GStatic Google Static Content Facebook Domain Insights Wix CoolText
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Emerge Health
Emerge Health is an innovative, specialised Australian pharmaceutical company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Neopharm Labs
Neopharm Labs operates as a full-service pharmaceutical testing laboratory.
NeuroproteXeon
NeuroproteXeon is a clinical-stage pharmaceutical and drug delivery device company.
Current Employees Featured
Founder
Official Site Inspections
http://www.neurocentria.com Semrush global rank: 7.9 M Semrush visits lastest month: 410
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Neurocentria"
Home | Neurocentria Inc.
Proprietary compound shown to improve brain health. Marketed since 2012 with approximately 500,000 customers / year.See details»
About - Neurocentria Inc.
Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depression and Alzheimer’s disease.See details»
Neurocentria, Inc. - LinkedIn
Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depression and...See details»
Neurocentria - Crunchbase Company Profile & Funding
Neurocentria is a clinical-stage pharmaceutical company founded with the mission to discover and develop treatments for neurological diseases, including cognitive impairment and neuropsychiatric disorders.See details»
People and Career - Neurocentria Inc.
Neurocentria strives to foster a collaborative work environment that empowers employees and allows the company to move forward towards success. We value everyone's ideas and …See details»
Neurocentria, Inc. Company Profile | Walnut Creek, CA
Find company research, competitor information, contact details & financial data for Neurocentria, Inc. of Walnut Creek, CA. Get the latest business insights from Dun & Bradstreet.See details»
Neurocentria, Inc. - VentureRadar
Website: http://www.neurocentria.com/ Develops treatments for neurological diseases, including cognitive impairment and neuropsychiatric disorders, focusing on synaptic function and …See details»
Neurocentria Company Profile 2024: Valuation, …
Provider of pharmaceutical research intended to discover and develop treatments for neurological diseases, including cognitive impairment and neuropsychiatric disorders. The company offers therapeutical research for neurological …See details»
New Research Study Reveals Critical Role of Magnesium in
May 30, 2024 · The study, conducted by neuroscientists from Neurocentria and Tsinghua University, provides novel insights into how magnesium levels in the brain control the …See details»
New Research Study Reveals Critical Role of …
May 30, 2024 · Neurocentria is developing NRCT-101SR, designed to promote magnesium delivery into the brain's synaptic terminals. NRCT-101SR has been shown to improve learning and memory and emotional...See details»
Neurocentria - Overview, News & Similar companies - ZoomInfo
Feb 14, 2022 · Neurocentria contact info: Phone number: (925) 954-4868 Website: www.neurocentria.com What does Neurocentria do? Neurocentria is a clinical stage …See details»
Leadership Team - Neurocentria Inc.
Former Director, The Division of Psychiatry Products, Center for Drug Evaluation and Research, FDA.See details»
New Research Study Reveals Critical Role of Magnesium in …
May 30, 2024 · The study, conducted by neuroscientists from Neurocentria and Tsinghua University, provides novel insights into how magnesium levels in the brain control the …See details»
Neurocentria Obtains FDA Approval to Conduct Pivotal Phase
WALNUT CREEK, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, …See details»
Neurocentria’s Lead Compound MMFS-01 Improves Brain Age by …
Oct 28, 2015 · Neurocentria’s novel approach reverses synaptic loss which is a key predictor of cognitive decline. The company’s lead compound for Alzheimer’s disease, MMFS-01, is based …See details»
Neurocentria Obtains FDA Approval to Conduct Pivotal Phase …
WALNUT CREEK, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, …See details»
Science | Neurocentria Inc.
Neurocentria's Path Forward: • Synapse loss is hallmark of AD; NRCT-101SR. prevents synapse loss • Clinical data shows NRCT-101SR improves cognition. and mood in older adults and …See details»
Working at Neurocentria - Glassdoor
Neurocentria is a clinical-stage pharmaceutical company founded with the mission to discover and develop treatments for neurological diseases, including cognitive impairment and …See details»
Neurocentria Publishes Peer-Reviewed Paper Showing Mechanism …
Oct 28, 2015 · Neurocentria, Inc. announced today the publication of a scientific paper showing how its candidate drug, LÂ-Threonic acid Magnesium salt (L-TAMS), reverses cognitive …See details»
Neuroscience News Science Magazine - Research Articles
Neuroscience News is an independent open access science magazine. Since 2001, we have featured neuroscience research news from labs, universities, hospitals and news departments …See details»